Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
SL-172154 by Shattuck Labs for Epithelial Ovarian Cancer: Likelihood of Approval
SL-172154 is under clinical development by Shattuck Labs and currently in Phase I for Epithelial Ovarian Cancer. According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Shattuck Labs's SL-172154?
SL-172154 is a fusion protein commercialized by Shattuck Labs, with a leading Phase I program in Metastatic Ovarian Cancer. According...
SL-172154 by Shattuck Labs for Myelodysplastic Syndrome: Likelihood of Approval
SL-172154 is under clinical development by Shattuck Labs and currently in Phase I for Myelodysplastic Syndrome. According to GlobalData, Phase...
SL-172154 by Shattuck Labs for Refractory Acute Myeloid Leukemia: Likelihood of Approval
SL-172154 is under clinical development by Shattuck Labs and currently in Phase I for Refractory Acute Myeloid Leukemia. According to...
SL-172154 by Shattuck Labs for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
SL-172154 is under clinical development by Shattuck Labs and currently in Phase I for Relapsed Acute Myeloid Leukemia. According to...